Ascentage reports Phase I safety data for IAP inhibitor in solid tumors

Ascentage Pharma Group Corp. Ltd. (Hong Kong, China) said IV APG-1387 once every week for three out of four weeks in each 28-day cycle was well tolerated with manageable adverse events in 28 evaluable patients with advanced solid tumors in a Phase I trial. The data were released in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago.

The most common treatment-emergent adverse events reported were vomiting, abdominal pain, anemia, cough, headache, elevated aspartate aminotransferase (AST) levels and ventricular arrhythmia. The maximum tolerated dose (MTD) has not yet been reached...